Clinical trials: Viral Respiratory Infection
Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)
The study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical study of the efficacy and safety of AMY-101, a potent C3 inhibitor, for the management of patients with ARDS caused by SARS-CoV-2…
- Trial name
- SAVE (NCT04395456)
- Testing
- AMY-101, WFI 5% glucose
- Volunteers
- 144 people
- Sponsor
- Amyndas Pharmaceuticals S.A.
COVID-19 Pneumonia
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
- Trial name
- NCT04561180
- Testing
- EG-009A, Standard of Care, Dexamethasone
- Sponsor
- Evergreen Therapeutics, Inc.
SARS-CoV-2 Infection
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test)…
- Trial name
- SCORPIO-PEP (NCT05897541)
- Testing
- S-217622
- Where
- 178 sites in United States, Argentina and 3 more
- Volunteers
- 3,701 people, healthy volunteers welcome
- Sponsor
- Shionogi
COVID-19 Pandemic
NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
This is a prospective, multicenter, randomized (3:1), placebo- controlled, parallel-group, double-blind trial. Patients will be randomized into two arms of treatment: Placebo + SoC (N=30) NanoManganese® + SoC (N=90) Patients will…
- Trial name
- NCT05451654
- Testing
- Experimental drug
- Where
- Brazil
- Volunteers
- 7 people
- Sponsor
- Medesis Pharma SA
Influenza
FLU A+B Nasal Swab Clinical Study
The purpose of this clinical study is to obtain clearance for the nasal swab sample type by demonstrating the performance characteristics of the FLU A+B Test versus standard laboratory culture for Influenza A and B viruses using…
- Trial name
- FLUA+B (NCT00636662)
- Testing
- Non-invasive diagnostic testing
- Where
- 5 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Response Biomedical Corp.
COVID-19
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from…
- Trial name
- NCT04295551
- Testing
- Lopinavir / ritonavir tablets combined with Xiyanping injection, Lopinavir/ritonavir treatment
- Volunteers
- 80 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COVID-19
Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
This open label, randomized, controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in COVID-19 subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate…
- Trial name
- NCT04573153
- Testing
- Hydroxychloroquine + Metabolic cofactor supplementation, Hydroxychloroquine + Sorbitol
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- ScandiBio Therapeutics AB
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
COVID-19
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19.
- Trial name
- NCT04411628
- Testing
- LY3819253
- Where
- 11 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Covid19
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
- Trial name
- NCT04532294
- Testing
- BGB DXP593
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
COVID-19
Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19
This is a double-blind, multicentre, multinational study to evaluate the safety and collect preliminary efficacy data of Codivir drug product in 130 hospitalized adults with moderate COVID-19 symptoms.
- Trial name
- NCT05218356
- Testing
- Covidir injections, Quantitative PCR SARS-CoV-2, IgM and IgG dosage
- Where
- 5 sites in Brazil
- Volunteers
- 130 people
- Sponsor
- Code Pharma
Hepatitis B, Chronic
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks.
- Trial name
- NCT00537537
- Testing
- Telbivudine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV-2
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
- Trial name
- NCT06130345
- Testing
- SPIKEVAX
- Where
- United States
- Volunteers
- 15,196,685 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
- Trial name
- TACKLE (NCT04723394)
- Testing
- AZD7442
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 910 people
- Sponsor
- AstraZeneca
SARS-CoV-2 Infection
Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.
This is a phase II/III parallel, double-blind, active-controlled, non-inferiority study to evaluate immunogenicity and safety of a booster immunization scheme of a single intramuscular dose of the recombinant vaccine against…
- Trial name
- NCT05710783
- Testing
- AVX-COVID/12, ChAdOx-1-S[recombinant]
- Where
- 14 sites in Mexico
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
Continuous Renal Replacement Therapy, Pulmonary Edema
C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19
The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19…
- Conditions
- Continuous Renal Replacement Therapy, Pulmonary Edema, COVID-19
- Trial name
- NCT04537975
- Testing
- C2Rx, Standard of Care (SOC)
- Sponsor
- SeaStar Medical
Respiratory Syncytial Virus
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to <60 years.
- Trial name
- NCT06067230
- Testing
- mRNA-1345
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 1,153 people
- Sponsor
- ModernaTX, Inc.
COVID-19 Disease
A Study of LAM-002A for the Prevention of Progression of COVID-19
This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
- Trial name
- NCT04446377
- Testing
- Apilimod Dimesylate Capsule
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- IRulya Therapeutics Inc.
Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV)
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
- Trial name
- NCT07764237
- Testing
- mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3)
- Where
- 10 sites in Canada, United Kingdom
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.